Royal Medical Private Limited

Royal Medical Private Limited, incorporated on May 27, 2005, is a private unlisted company based in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U52310MH2005PTC153573. Its authorized capital is ₹50.0 lakhs, with a paid-up capital of ₹25.0 lakhs. The registered office is located at Office No. 2, 1st Floor, Sunbeam Chambers, 7, New Marine Lines, Opp. Liberty Cinema Building, Mumbai, Maharashtra 400020.

Royal Medical Private Limited specializes in the wholesale trading of pharmaceutical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company has been operational for over two decades, indicating a stable presence in the pharmaceutical export sector. As of the latest available data, the company has a paid-up capital of ₹25.0 lakhs, reflecting its financial standing.

Specific details regarding Royal Medical Private Limited's manufacturing facilities are not publicly disclosed. The company is primarily engaged in the wholesale trading of pharmaceutical products, suggesting that it may source its products from third-party manufacturers. Without explicit information on in-house manufacturing capabilities, it is prudent to assume that the company relies on external manufacturing partners for its product offerings.

The leadership team of Royal Medical Private Limited comprises:

• Asan Mohideen Nagoormeeran Sheik Packeer: Whole-Time Director
• Saumil Mahendra Gandhi: Director
• Mahendra Mukundlal Gandhi: Managing Director

These individuals are responsible for steering the company's strategic direction and operations.

Royal Medical Private Limited's export activities are primarily focused on the pharmaceutical sector, with a total export value of $96,000 USD across 71 shipments. The company's product portfolio includes six products across two therapeutic categories: Advanced Oncology (69.8%) and Antiviral & HIV Medications (30.2%). Notably, the company holds the #1 market position in Cabozantinib, with a 9.4% market share. However, specific details regarding regulatory filings, approvals, and market access status in the US, EU, UK, Australia, and Japan are not publicly available. The absence of this information suggests that the company may not have significant market penetration in these regions or that such data is not disclosed.

Royal Medical Private Limited's export data indicates a focus on markets in Africa, South Africa, and potentially other regions. The company's engagement in these markets is facilitated by its membership in the Pharmaceuticals Export Promotion Council, which supports Indian pharmaceutical exporters in accessing global markets. While the company has a presence in emerging markets, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly disclosed.

Royal Medical Private Limited's export portfolio is heavily concentrated, with the top five products accounting for 96.7% of total exports. This concentration indicates a focused product strategy but also exposes the company to risks associated with market fluctuations in these specific products. The company's geographic strategy appears to be centered on select international markets, particularly in Africa and South Africa, as indicated by its membership in the Pharmaceuticals Export Promotion Council. However, the lack of detailed information on market diversification and expansion plans suggests that the company may benefit from exploring additional markets to mitigate concentration risks.

Specific information regarding Royal Medical Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The absence of this information suggests that the company may not have significant operations or approvals in the United States market. Without explicit data, it is challenging to assess the company's standing with the FDA.

There is no publicly available information indicating that Royal Medical Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The lack of such certifications may limit the company's ability to access certain international markets that require these standards. However, the company's membership in the Pharmaceuticals Export Promotion Council suggests a commitment to international trade and adherence to certain quality standards.

Royal Medical Private Limited is registered with the Ministry of Corporate Affairs (MCA) under the Corporate Identification Number (CIN) U52310MH2005PTC153573. The company's authorized capital is ₹50.0 lakhs, with a paid-up capital of ₹25.0 lakhs. Specific details regarding manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. The absence of this information suggests that the company may not have significant manufacturing operations or regulatory approvals within India.

There is no publicly available information regarding Form 483 observations, warning letters, or import alerts associated with Royal Medical Private Limited. The absence of such data indicates that the company has not faced significant regulatory actions in the public domain.

Royal Medical Private Limited operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. The company's top five products—Cabozantinib, Axitinib, Ledipasvir, Pazopanib, and Ibrutinib—are all oncology medications, indicating a specialized product portfolio. While specific market share data for competitors in these therapeutic categories is not available, the company's concentration in a niche segment may position it against specialized competitors in the oncology pharmaceutical market. The lack of detailed competitive analysis suggests that the company may benefit from conducting a comprehensive market study to identify key competitors and assess its competitive positioning.

Royal Medical Private Limited's key differentiators include its specialized focus on oncology medications, particularly Cabozantinib, where it holds the #1 market position with a 9.4% market share. This specialization may allow the company to leverage expertise and establish strong relationships within the oncology pharmaceutical sector. However, the company's heavy reliance on a limited product portfolio (top five products accounting for 96.7% of total exports) may pose risks related to market concentration.

Royal Medical Private Limited's current strategic direction appears to be focused on exporting a specialized portfolio of oncology medications, with a particular emphasis on Cabozantinib. The company's membership in the Pharmaceuticals Export Promotion Council indicates an interest in expanding its international presence. However, the lack of detailed information on market diversification, regulatory approvals, and certifications suggests that the company may need to enhance its strategic positioning by obtaining relevant certifications, expanding its product portfolio, and exploring new markets to mitigate risks associated with market concentration.

Royal Medical Private Limited's export data indicates a consistent volume of shipments, with 71 shipments totaling $96,000 USD. The company's focus on finished pharmaceutical formulations suggests a commitment to quality and compliance with international standards. However, the lack of detailed information regarding manufacturing facilities, regulatory approvals, and certifications makes it challenging to fully assess the reliability and consistency of the company's supply chain. Potential partners should conduct thorough due diligence to ensure alignment with their quality and regulatory requirements.

Importers should verify the following certifications when considering Royal Medical Private Limited as a supplier:

• WHO-GMP Certification: Ensures compliance with World Health Organization Good Manufacturing Practices. Verification can be done through the WHO's official website or by contacting the company directly.

• EU GMP Certification: Confirms adherence to European Union Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the company.

• ISO Certification: Indicates quality management standards. Verification can be performed through the International Organization for Standardization (ISO) or by contacting the company.

When conducting due diligence on Royal Medical Private Limited, consider the following steps:

• Verify Regulatory Approvals: Confirm the company's compliance with relevant regulatory bodies, including the CDSCO in India and international agencies.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities or third-party manufacturing partners to ensure quality standards are met.

• Review Financial Statements: Analyze the company's financial health through audited financial statements to assess stability and reliability.

• Check Certifications: Ensure the company holds necessary certifications, such as WHO-GMP, EU GMP, and ISO, to meet international standards.

• Evaluate Supply Chain Reliability: Assess the consistency and reliability of the company's supply